GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (NAS:NKTR) » Definitions » Cyclically Adjusted PB Ratio

NKTR (Nektar Therapeutics) Cyclically Adjusted PB Ratio : 0.39 (As of Jul. 09, 2025)


View and export this data going back to 1994. Start your Free Trial

What is Nektar Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-07-09), Nektar Therapeutics's current share price is $22.73. Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $58.84. Nektar Therapeutics's Cyclically Adjusted PB Ratio for today is 0.39.

The historical rank and industry rank for Nektar Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

NKTR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.12   Med: 7.73   Max: 130.74
Current: 0.4

During the past years, Nektar Therapeutics's highest Cyclically Adjusted PB Ratio was 130.74. The lowest was 0.12. And the median was 7.73.

NKTR's Cyclically Adjusted PB Ratio is ranked better than
76.25% of 678 companies
in the Biotechnology industry
Industry Median: 1.585 vs NKTR: 0.40

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Nektar Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $1.107. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $58.84 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Nektar Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Nektar Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Cyclically Adjusted PB Ratio Chart

Nektar Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.19 4.28 0.65 0.15 0.24

Nektar Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.32 0.33 0.24 0.17

Competitive Comparison of Nektar Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Nektar Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nektar Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nektar Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Nektar Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Nektar Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Nektar Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=22.73/58.84
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Nektar Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.107/134.9266*134.9266
=1.107

Current CPI (Mar. 2025) = 134.9266.

Nektar Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 3.983 100.684 5.338
201509 4.397 100.392 5.910
201512 0.713 99.792 0.964
201603 -0.030 100.470 -0.040
201606 -4.310 101.688 -5.719
201609 -7.387 101.861 -9.785
201612 8.628 101.863 11.429
201703 4.338 102.862 5.690
201706 0.326 103.349 0.426
201709 8.043 104.136 10.421
201712 8.258 104.011 10.713
201803 5.384 105.290 6.899
201806 161.860 106.317 205.416
201809 155.164 106.507 196.567
201812 148.464 105.998 188.982
201903 140.638 107.251 176.930
201906 133.501 108.070 166.678
201909 127.034 108.329 158.224
201912 119.435 108.420 148.634
202003 109.329 108.902 135.456
202006 105.380 108.767 130.725
202009 97.908 109.815 120.297
202012 89.730 109.897 110.167
202103 81.832 111.754 98.800
202106 73.863 114.631 86.940
202109 65.145 115.734 75.948
202112 54.954 117.630 63.035
202203 48.952 121.301 54.451
202206 36.716 125.017 39.626
202209 32.899 125.227 35.447
202212 29.165 125.222 31.425
202303 19.092 127.348 20.228
202306 15.539 128.729 16.287
202309 12.531 129.860 13.020
202312 10.266 129.419 10.703
202403 10.350 131.776 10.597
202406 6.494 132.554 6.610
202409 3.975 133.029 4.032
202412 4.904 133.157 4.969
202503 1.107 134.927 1.107

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nektar Therapeutics  (NAS:NKTR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Nektar Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nektar Therapeutics Business Description

Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Executives
Howard W Robin director, officer: President & CEO
Jonathan Zalevsky officer: Chief R&D Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Mark Andrew Wilson officer: SVP & General Counsel 1613 RAY DRIVE, BURLINGAME CA 94010
Robert Chess director, officer: Executive Chairman
Myriam Curet director 1020 KIFER ROAD, SUNNYVALE CA 94086
Jeffrey Robert Ajer director C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Sandra A. Gardiner officer: Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jillian B. Thomsen officer: VP & Chief Accounting Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Karin Eastham director C/O BURNHAM INSTITUTE FOR MEDICAL RESEAR, 10901 N. TORREY PINES ROAD, LA JOLLA CA 92037
Gil M Labrucherie officer: SVP, COO & CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
John Northcott officer: SVP & Chief Commercial Officer 455 MISSION BAY BOULEVARD SOUTH, C/O NEKTAR THERAPEUTICS, SAN FRANCISCO CA 94158
Diana Brainard director C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
R Scott Greer director 6207 E. INDIAN BEND RD, PARADISE VALLEY AZ 85253
Lutz Lingnau director 15 INDIAN HOLLOW ROAD, MENDHAM NJ 07945
Stephen K Doberstein officer: Chief Scientific Officer 129 ELSIE STREET, SAN FRANCISCO CA 94110